APA (7th ed.) Citation

J, D. C., J, G., A, V., N, K., C, C., H, G., . . . P, L. (2026). Imlifidase enables AAV gene therapy in a seropositive Crigler-Najjar patient: On the verge of a paradigm shift. Molecular therapy : the journal of the American Society of Gene Therapy, 34(5), 2571. https://doi.org/10.1016/j.ymthe.2026.04.018

Chicago Style (17th ed.) Citation

J, Do Cao, et al. "Imlifidase Enables AAV Gene Therapy in a Seropositive Crigler-Najjar Patient: On the Verge of a Paradigm Shift." Molecular Therapy : The Journal of the American Society of Gene Therapy 34, no. 5 (2026): 2571. https://doi.org/10.1016/j.ymthe.2026.04.018.

MLA (9th ed.) Citation

J, Do Cao, et al. "Imlifidase Enables AAV Gene Therapy in a Seropositive Crigler-Najjar Patient: On the Verge of a Paradigm Shift." Molecular Therapy : The Journal of the American Society of Gene Therapy, vol. 34, no. 5, 2026, p. 2571, https://doi.org/10.1016/j.ymthe.2026.04.018.